ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Promoter Sachidanand Hariram Upadhyay proposed reinvesting proceeds from his prior sale of shares into the company's medical device unit expansion.
Lord’s Mark Industries has advanced its AI-powered breast cancer screening technology to final clinical trial stages. The company targets a global commercial launch by April 2027.
Promoter Director Mr. Sachidanand H Upadhyay sold 1.04 crore shares on BSE for ₹87.39 Crore. Stake reduced from 77.54% to 75.11%.
Lord's Mark promoter Sachidanand Upadhyay disposed 1.04 crore shares via open market, cutting his stake from 77.54% to 75.11%.
Lord's Mark Industries completed Phase I Silvassa expansion, adding 18 surgical/orthopaedic SKUs (36 to 54). Commercial operations commence October 11, 2026.
Lord's Mark Industries is a MedTech and Renewable Energy conglomerate focused on high-margin diagnostic innovations and a ₹3,000+ Cr solar order pipeline.
The board approved a proposal for an Offer for Sale (OFS) of up to 3% of equity capital by promoters to meet minimum public shareholding requirements.
Lords Mark Industries Ltd has issued a notice for its 46th Annual General Meeting, scheduled to be held on September 30, 2026.
Lord's Mark Industries Limited has filed its 46th Annual Report for the financial year 2025-26 and the notice of its upcoming 46th Annual General Meeting.
Lords Mark Industries entered a strategic partnership with ARKALL Holdings for Caribbean healthcare expansion. The collaboration targets $100 million in export revenue from diagnostic and medical device commercialisation.
Lords Mark Industries reported Q1 FY27 results, achieving 280 Cr topline and 32 Cr bottom line. The firm is transitioning from traditional energy to high-margin MedTech and diagnostics.
Infomerics upgraded Lord's Mark Industries Limited's credit rating to IVR A-/Stable for long-term and IVR A2+ for short-term bank facilities totaling Rs. 260.37 Crore.
Lord's Mark Industries Limited scheduled its 46th Annual General Meeting for September 30, 2026. The company set September 23, 2026, as the cut-off date for e-voting.
Lord’s Mark Industries announced a major strategic expansion including a demerger of its energy business, incorporation of UK and Swiss subsidiaries, and the establishment of 50 dialysis centres.
Lords Mark Industries Ltd reported revenue from operations of ₹307.7 Cr and net profit of ₹33.2 Cr for Q1 FY27.
Lord's Mark Industries Limited received a manufacturing license for its Biomescan Analytics Platform. This platform is India's first licensed In Vitro Diagnostic Software for microbiome assessments.